Benuvia

Executive Summary

Benuvia is a specialized Contract Development and Manufacturing Organization (CDMO) headquartered in Austin, Texas, uniquely positioned to handle controlled substances including cannabinoids, psychedelics, and other small molecules. Founded in 2018, the company offers end-to-end services from drug discovery through commercial launch, helping clients navigate complex regulatory environments. With the growing interest in psychedelic-assisted therapies and cannabinoid-based medicines, Benuvia addresses a critical bottleneck in the supply chain: compliant, high-quality manufacturing of Schedule I and II substances. The company's purpose-built facilities and expertise in controlled substance handling provide a competitive advantage, as few CDMOs possess the necessary DEA licenses and infrastructure. As the psychedelics sector moves toward FDA approval for compounds like MDMA and psilocybin, Benuvia is well-positioned to capture a significant share of the outsourced manufacturing market. Benuvia's business model leverages the trend of pharmaceutical companies outsourcing complex manufacturing to reduce capital expenditure and regulatory risk. The company's integrated platform accelerates client timelines, offering a seamless transition from development to scale-up. Given the limited number of FDA-registered, DEA-compliant facilities in the US, Benuvia's capacity is a valuable asset. Near-term growth is driven by the expansion of clinical-stage psychedelic programs and increasing demand for GMP-grade cannabinoids. While the company is currently pre-clinical stage in terms of proprietary products, its CDMO operations generate recurring revenue. The combination of a defensible niche, regulatory barriers to entry, and tailwinds in psychedelics and cannabinoids supports a favorable outlook.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new GMP manufacturing partnership with a psychedelics biotech60% success
• Q4 2026DEA license renewal or expansion for additional controlled substances80% success
• Q1 2027Facility capacity expansion or new site acquisition to meet demand50% success